KALA - Kala Pharmaceuticals GAAP EPS of -$0.68 misses by $0.29 revenue of $1.87M misses by $1.55M
Kala Pharmaceuticals press release (NASDAQ:KALA): Q4 GAAP EPS of -$0.68 misses by $0.29. Revenue of $1.86M (-17% Y/Y) misses by $1.55M. As of December 31, 2021, cash and cash equivalents of $92.1 million, compared to $124.5 million of cash, cash equivalents and short-term investments as of September 30, 2021. Shares +5.71% PM.
For further details see:
Kala Pharmaceuticals GAAP EPS of -$0.68 misses by $0.29, revenue of $1.87M misses by $1.55M